Kyle Fink

Title(s)Assistant Professor, Neurology
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    2020 American Society for Neural Therapy and Repair Conference
    NIH R13NS118601Apr 1, 2020 - Mar 31, 2021
    Role: Principal Investigator
    NIH R13NS111902Apr 1, 2019 - Mar 31, 2020
    Role: Principal Investigator
    MSCs engineered to produce Brain-Derived Neurotrophic Factor for the Treatment of Huntington's disease
    NIH R01NS102486Jul 1, 2017 - Jun 30, 2021
    Role: Co-Principal Investigator
    Novel epigenetic targets for silencing the Huntingtons disease mutation
    NIH F32NS090722Sep 15, 2014 - Sep 14, 2016
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Epigenetic editing for autosomal dominant neurological disorders. Front Genome Ed. 2024; 6:1304110. Waldo JJ, Halmai JANM, Fink KD. PMID: 38510848; PMCID: PMC10950933.
      View in: PubMed   Mentions:
    2. Biologics in brain repair. Brain Res Bull. 2023 10 01; 202:110757. Modo M, Fink K, Rossignol J. PMID: 37683702.
      View in: PubMed   Mentions:    Fields:    
    3. Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman syndrome mouse model. Mol Ther. 2023 04 05; 31(4):1088-1105. O'Geen H, Beitnere U, Garcia MS, Adhikari A, Cameron DL, Fenton TA, Copping NA, Deng P, Lock S, Halmai JANM, Villegas IJ, Liu J, Wang D, Fink KD, Silverman JL, Segal DJ. PMID: 36641623; PMCID: PMC10124086.
      View in: PubMed   Mentions: 3     Fields:    
    4. Touchscreen cognitive deficits, hyperexcitability and hyperactivity in males and females using two models of Cdkl5 deficiency. Hum Mol Genet. 2022 09 10; 31(18):3032-3050. Adhikari A, Buchanan FKB, Fenton TA, Cameron DL, Halmai JANM, Copping NA, Fink KD, Silverman JL. PMID: 35445702; PMCID: PMC9476626.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    5. Polyamine Metabolites as Biomarkers in Head and Neck Cancer Biofluids. Diagnostics (Basel). 2022 Mar 24; 12(4). DeFelice BC, Fiehn O, Belafsky P, Ditterich C, Moore M, Abouyared M, Beliveau AM, Farwell DG, Bewley AF, Clayton SM, Archard JA, Pavlic J, Rao S, Kuhn M, Deng P, Halmai J, Fink KD, Birkeland AC, Anderson JD. PMID: 35453845; PMCID: PMC9024570.
      View in: PubMed   Mentions: 2  
    6. An in vivo Cell-Based Delivery Platform for Zinc Finger Artificial Transcription Factors in Pre-clinical Animal Models. Front Mol Neurosci. 2021; 14:789913. Deng P, Halmai JANM, Beitnere U, Cameron D, Martinez ML, Lee CC, Waldo JJ, Thongphanh K, Adhikari A, Copping N, Petkova SP, Lee RD, Lock S, Palomares M, O'Geen H, Carter J, Gonzalez CE, Buchanan FKB, Anderson JD, Fierro FA, Nolta JA, Tarantal AF, Silverman JL, Segal DJ, Fink KD. PMID: 35153670; PMCID: PMC8829036.
      View in: PubMed   Mentions: 1  
    7. Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome. Neurotherapeutics. 2021 07; 18(3):1535-1547. Copping NA, McTighe SM, Fink KD, Silverman JL. PMID: 34528170; PMCID: PMC8608975.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    8. Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells. Hum Mol Genet. 2021 06 09; 30(12):1067-1083. Adhikari A, Copping NA, Beegle J, Cameron DL, Deng P, O'Geen H, Segal DJ, Fink KD, Silverman JL, Anderson JS. PMID: 33856035; PMCID: PMC8188406.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    9. A novel Huntington's disease mouse model to assess the role of neuroinflammation on disease progression and to develop human cell therapies. Stem Cells Transl Med. 2021 07; 10(7):1033-1043. Dahlenburg H, Cameron D, Yang S, Bachman A, Pollock K, Cary W, Pham M, Hendrix K, White J, Nelson H, Deng P, Anderson JS, Fink K, Nolta J. PMID: 33710799; PMCID: PMC8235129.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    10. Cell-Based Delivery Approaches for DNA-Binding Domains to the Central Nervous System. Curr Neuropharmacol. 2021; 19(12):2125-2140. Deng P, Halmai J, Waldo JJ, Fink KD. PMID: 33998992; PMCID: PMC9185769.
      View in: PubMed   Mentions:    Fields:    
    11. The iNs and Outs of Direct Reprogramming to Induced Neurons. Front Genome Ed. 2020; 2:7. Carter JL, Halmai JANM, Fink KD. PMID: 34713216; PMCID: PMC8525349.
      View in: PubMed   Mentions: 4  
    12. Artificial escape from XCI by DNA methylation editing of the CDKL5 gene. Nucleic Acids Res. 2020 03 18; 48(5):2372-2387. Halmai JANM, Deng P, Gonzalez CE, Coggins NB, Cameron D, Carter JL, Buchanan FKB, Waldo JJ, Lock SR, Anderson JD, O'Geen H, Segal DJ, Nolta J, Fink KD. PMID: 31925439; PMCID: PMC7049732.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    13. Translational outcomes in a full gene deletion of ubiquitin protein ligase E3A rat model of Angelman syndrome. Transl Psychiatry. 2020 01 27; 10(1):39. Berg EL, Pride MC, Petkova SP, Lee RD, Copping NA, Shen Y, Adhikari A, Fenton TA, Pedersen LR, Noakes LS, Nieman BJ, Lerch JP, Harris S, Born HA, Peters MM, Deng P, Cameron DL, Fink KD, Beitnere U, O'Geen H, Anderson AE, Dindot SV, Nash KR, Weeber EJ, Wöhr M, Ellegood J, Segal DJ, Silverman JL. PMID: 32066685; PMCID: PMC7026078.
      View in: PubMed   Mentions: 26     Fields:    Translation:Animals
    14. Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner. Epigenetics Chromatin. 2019 May 03; 12(1):26. O'Geen H, Bates SL, Carter SS, Nisson KA, Halmai J, Fink KD, Rhie SK, Farnham PJ, Segal DJ. PMID: 31053162; PMCID: PMC6498470.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    15. Primed mesenchymal stem cells package exosomes with metabolites associated with immunomodulation. Biochem Biophys Res Commun. 2019 05 14; 512(4):729-735. Showalter MR, Wancewicz B, Fiehn O, Archard JA, Clayton S, Wagner J, Deng P, Halmai J, Fink KD, Bauer G, Fury B, Perotti NH, Apperson M, Butters J, Belafsky P, Farwell G, Kuhn M, Nolta JA, Anderson JD. PMID: 30926165; PMCID: PMC6682414.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    16. Exosomes Derived from Human Primed Mesenchymal Stem Cells Induce Mitosis and Potentiate Growth Factor Secretion. Stem Cells Dev. 2019 03 15; 28(6):398-409. Yuan O, Lin C, Wagner J, Archard JA, Deng P, Halmai J, Bauer G, Fink KD, Fury B, Perotti NH, Walker JE, Pollock K, Apperson M, Butters J, Belafsky P, Farwell DG, Kuhn M, Nolta J, Anderson JD. PMID: 30638129; PMCID: PMC6441283.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    17. Spatial memory in Huntington's disease: A comparative review of human and animal data. Neurosci Biobehav Rev. 2019 03; 98:194-207. Glikmann-Johnston Y, Fink KD, Deng P, Torrest A, Stout JC. PMID: 30658070.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    18. Design, Construction, and Application of Transcription Activation-Like Effectors. Methods Mol Biol. 2019; 1937:47-58. Deng P, Carter S, Fink K. PMID: 30706389.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    19. Mesenchymal stem cell-based therapy for ischemic stroke. Chinese Neurosurgical Journal. 2016 Dec 1; 2(1):36. Anderson AJ, Pham PM, Contreras CZ, Hoon HM, Fink FK, Johansson JH, Rossignol RJ, Dunbar DG, Showalter SM, Fiehn FO, Bramlett BC, Bardini BR, Bauer BG, Fury FB, Hendrix HK, Chedin CF, EL-Andaloussi ES, Hwang HB, Mulligan MM, Lehtiö LJ, Nolta NJ. .
      View in: Publisher Site   Mentions:
    20. Engineered BDNF producing cells as a potential treatment for neurologic disease. Expert Opin Biol Ther. 2016 08; 16(8):1025-33. Deng P, Anderson JD, Yu AS, Annett G, Fink KD, Nolta JA. PMID: 27159050; PMCID: PMC5762114.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimals
    21. Clinical trial perspective for adult and juvenile Huntington's disease using genetically-engineered mesenchymal stem cells. Neural Regen Res. 2016 May; 11(5):702-5. Deng P, Torrest A, Pollock K, Dahlenburg H, Annett G, Nolta JA, Fink KD. PMID: 27335539; PMCID: PMC4904446.
      View in: PubMed   Mentions: 16  
    22. Comprehensive Proteomic Analysis of Mesenchymal Stem Cell Exosomes Reveals Modulation of Angiogenesis via Nuclear Factor-KappaB Signaling. Stem Cells. 2016 Mar; 34(3):601-13. Anderson JD, Johansson HJ, Graham CS, Vesterlund M, Pham MT, Bramlett CS, Montgomery EN, Mellema MS, Bardini RL, Contreras Z, Hoon M, Bauer G, Fink KD, Fury B, Hendrix KJ, Chedin F, El-Andaloussi S, Hwang B, Mulligan MS, Lehtiö J, Nolta JA. PMID: 26782178; PMCID: PMC5785927.
      View in: PubMed   Mentions: 248     Fields:    Translation:HumansCells
    23. Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts. Cell Transplant. 2016; 25(4):677-86. Fink KD, Deng P, Gutierrez J, Anderson JS, Torrest A, Komarla A, Kalomoiris S, Cary W, Anderson JD, Gruenloh W, Duffy A, Tempkin T, Annett G, Wheelock V, Segal DJ, Nolta JA. PMID: 26850319; PMCID: PMC6476541.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    24. Mesenchymal Stem Cells as Treatment for Behavioral Deficits and Neuropathology in the 5xFAD Mouse Model of Alzheimer's Disease. Cell Transplant. 2016; 25(4):687-703. Matchynski-Franks JJ, Pappas C, Rossignol J, Reinke T, Fink K, Crane A, Twite A, Lowrance SA, Song C, Dunbar GL. PMID: 26850119.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    25. Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models. Mol Ther. 2016 05; 24(5):965-77. Pollock K, Dahlenburg H, Nelson H, Fink KD, Cary W, Hendrix K, Annett G, Torrest A, Deng P, Gutierrez J, Nacey C, Pepper K, Kalomoiris S, D Anderson J, McGee J, Gruenloh W, Fury B, Bauer G, Duffy A, Tempkin T, Wheelock V, Nolta JA. PMID: 26765769; PMCID: PMC4881765.
      View in: PubMed   Mentions: 86     Fields:    
    26. Reductions in behavioral deficits and neuropathology in the R6/2 mouse model of Huntington's disease following transplantation of bone-marrow-derived mesenchymal stem cells is dependent on passage number. Stem Cell Res Ther. 2015 Feb 19; 6:9. Rossignol J, Fink KD, Crane AT, Davis KK, Bombard MC, Clerc S, Bavar AM, Lowrance SA, Song C, Witte S, Lescaudron L, Dunbar GL. PMID: 25971780; PMCID: PMC4429666.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    27. Bone-marrow-derived mesenchymal stem cells attenuate cognitive deficits in an endothelin-1 rat model of stroke. Restor Neurol Neurosci. 2015; 33(4):579-88. Lowrance SA, Fink KD, Crane A, Matyas J, Dey ND, Matchynski JJ, Thibo T, Reinke T, Kippe J, Hoffman C, Sandstrom M, Rossignol J, Dunbar GL. PMID: 23902985.
      View in: PubMed   Mentions: 7     Fields:    Translation:Animals
    28. Developing stem cell therapies for juvenile and adult-onset Huntington's disease. Regen Med. 2015; 10(5):623-46. Fink KD, Deng P, Torrest A, Stewart H, Pollock K, Gruenloh W, Annett G, Tempkin T, Wheelock V, Nolta JA. PMID: 26237705; PMCID: PMC6785015.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    29. Intrastriatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington's disease. Stem Cells Transl Med. 2014 May; 3(5):620-31. Fink KD, Crane AT, Lévêque X, Dues DJ, Huffman LD, Moore AC, Story DT, Dejonge RE, Antcliff A, Starski PA, Lu M, Lescaudron L, Rossignol J, Dunbar GL. PMID: 24657963; PMCID: PMC4006485.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    30. Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioral sparing in a transgenic rat model of Huntington's disease. Stem Cells. 2014 Feb; 32(2):500-9. Rossignol J, Fink K, Davis K, Clerc S, Crane A, Matchynski J, Lowrance S, Bombard M, Dekorver N, Lescaudron L, Dunbar GL. PMID: 23939879.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    31. Combining enriched environment and induced pluripotent stem cell therapy results in improved cognitive and motor function following traumatic brain injury. Restor Neurol Neurosci. 2014; 32(5):675-87. Dunkerson J, Moritz KE, Young J, Pionk T, Fink K, Rossignol J, Dunbar G, Smith JS. PMID: 25079980.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    32. Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6/2 mice: behavioral and neuropathological analysis. Stem Cell Res Ther. 2013 Oct 24; 4(5):130. Fink KD, Rossignol J, Crane AT, Davis KK, Bombard MC, Bavar AM, Clerc S, Lowrance SA, Song C, Lescaudron L, Dunbar GL. PMID: 24456799; PMCID: PMC3854759.
      View in: PubMed   Mentions: 28     Fields:    Translation:AnimalsCells
    33. Survival and differentiation of adenovirus-generated induced pluripotent stem cells transplanted into the rat striatum. Cell Transplant. 2014; 23(11):1407-23. Fink KD, Rossignol J, Lu M, Lévêque X, Hulse TD, Crane AT, Nerriere-Daguin V, Wyse RD, Starski PA, Schloop MT, Dues DJ, Witte SJ, Song C, Vallier L, Nguyen TH, Naveilhan P, Anegon I, Lescaudron L, Dunbar GL. PMID: 23879897.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    34. Early cognitive dysfunction in the HD 51 CAG transgenic rat model of Huntington's disease. Behav Neurosci. 2012 Jun; 126(3):479-87. Fink KD, Rossignol J, Crane AT, Davis KK, Bavar AM, Dekorver NW, Lowrance SA, Reilly MP, Sandstrom MI, von Hörsten S, Lescaudron L, Dunbar GL. PMID: 22642889.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    35. Assessing the potential clinical utility of transplantations of neural and mesenchymal stem cells for treating neurodegenerative diseases. Methods Mol Biol. 2012; 879:147-64. Lescaudron L, Boyer C, Bonnamain V, Fink KD, Lévêque X, Rossignol J, Nerrière-Daguin V, Malouet AC, Lelan F, Dey ND, Michel-Monigadon D, Lu M, Neveu I, von Hörsten S, Naveilhan P, Dunbar GL. PMID: 22610559.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    36. The effects of acute voluntary wheel running on recovery of function following medial frontal cortical contusions in rats. Restor Neurol Neurosci. 2012; 30(4):325-33. Crane AT, Fink KD, Smith JS. PMID: 22596352.
      View in: PubMed   Mentions: 12     Fields:    Translation:Animals
    37. Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes. Behav Brain Res. 2011 Mar 01; 217(2):369-78. Rossignol J, Boyer C, Lévèque X, Fink KD, Thinard R, Blanchard F, Dunbar GL, Lescaudron L. PMID: 21070819.
      View in: PubMed   Mentions: 39     Fields:    Translation:AnimalsCells